866-997-4948(US-Canada Toll Free)

Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Sep 2011

Category :

Ovarian Cancer

No. of Pages : 32 Pages


GlobalDatas pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Karenitecin sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

 

 

  • Therapy area profile including patient population for the US, EU and Japan (seven major markets)
  • Analysis and review of Karenitecin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Karenitecin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Karenitecin in the seven major markets


Reasons to buy

 

 

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets


Keywords

Karenitecin, ovarian cancer, BNP 1350, anti-cancer chemotherapy drug, synthetic silicon-containing agent, camptothecin, anti-neoplastic, Bionumerik, second line treatment for ovarian cancer, second line treatment for stage III and stage IV platinum resistant ovarian cancer, metastatic melanoma, advanced non-small cell lung cancer, small cell lung cancer, colorectal cancer, lymphomas, breast cancer, topoisomerase I, sales forecast, phase III/pipeline, competitors to karenetecin Avastin, Doxil, AMG386, EC145

 

 

Table of Contents

 

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Market Forecasts Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Therapy Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12


5 Karenitecin 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Factors Affecting Sales of Karenitecin 16
5.4.1 Good Safety Profile 16
5.4.2 Large Unmet Need 16
5.4.3 Low Efficacy 16
5.5 Drug Evaluation 16
5.5.1 Drug Risk Benefit Score 16
5.5.2 Intensity of Competition 17
5.5.3 Sales Forecasts 18
5.5.4 Target Patient Pool of Karenitecin 18
5.5.5 Dosing 18
5.5.6 Market Penetration 19
5.5.7 Annual Cost of Therapy 19
5.6 Sales Projections of Karenitecin 20


6 Ovarian Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 List of Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 31
6.4 Drug Sales Estimates Model 31
6.5 Contact Us 31
6.6 Disclaimer 31
6.7 Sources 32

List of Table


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Detailed TNM Classification 13
Table 3: Drug Risk Benefit Score 17
Table 4: Annual Cost of Therapy of Karenticin, 2014 19
Table 5: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 20142020 20
Table 6: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 20142020 21
Table 7: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20142020 22
Table 8: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 20142020 23
Table 9: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20142020 24
Table 10: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20142020 25
Table 11: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20142020 26
Table 12: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20142020 27

List of Chart


Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Karenitecin 18
Figure 9: Karenitecin, Ovarian Cancer, Global, Sales Forecasts ($m), 20142020 20
Figure 10: Karenitecin, Ovarian Cancer, The US, Sales Forecasts ($m), 20142020 21
Figure 11: Karenitecin, Ovarian Cancer, The UK, Sales Forecasts ($m), 20142020 22
Figure 12: Karenitecin, Ovarian Cancer, France, Sales Forecasts ($m), 20142020 23
Figure 13: Karenitecin, Ovarian Cancer, Germany, Sales Forecasts ($m), 20142020 24
Figure 14: Karenitecin, Ovarian Cancer, Italy, Sales Forecasts ($m), 20142020 25
Figure 15: Karenitecin, Ovarian Cancer, Spain, Sales Forecasts ($m), 20142020 26
Figure 16: Karenitecin, Ovarian Cancer, Japan, Sales Forecasts ($m), 20142020 27
Figure 17: Karenitecin , Ovarian Cancer, Sales Distribution (%), By Country, 2020 28
Figure 18: Patients Approved for the Drug 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *